Sinco Pharmaceutical Holdings (HKSE:06833) Total Current Assets : HK$1,615 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Sinco Pharmaceutical Holdings's total current assets for the quarter that ended in Dec. 2024 was HK$1,615 Mil.

Sinco Pharmaceutical Holdings Total Current Assets Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings Total Current Assets Chart

Sinco Pharmaceutical Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

1,192.22

1,186.48

1,136.15

1,567.70

1,614.53

Sinco Pharmaceutical Holdings Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Current Assets	Get a 7-Day Free Trial															1,136.15	1,303.05	1,567.70	1,452.36	1,614.53

Sinco Pharmaceutical Holdings Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Sinco Pharmaceutical Holdings's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	329.185	+	650.511	+	376.18	+	258.657
	=	1,615

Sinco Pharmaceutical Holdings's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	329.185	+	650.511	+	376.18	+	258.657
	=	1,615

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Sinco Pharmaceutical Holdings (HKSE:06833) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Sinco Pharmaceutical Holdings's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	329.185	-	1428.058	+	0.75 * 544.145	+	0.5 * 376.18
=	-503

Sinco Pharmaceutical Holdings Total Current Assets Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinco Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN

Website

https://www.sinco-pharm.com

Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.

Executives

Huang Zhijian	2305 Beneficiary of a trust
Fullwealth Holdings Limited	2201 Interest of corporation controlled by you
Risun Investments Limited	2101 Beneficial owner
Wickhams Cay Trust Company Limited	2301 Trustee
Huang Xiangbin	2307 Founder of a discretionary trust who can infl

Sinco Pharmaceutical Holdings Headlines

No Headlines